Global footprint GCT operates through 11 own offices across Eastern Europe, the US, and beyond, plus a network of Scandinavia/Western Europe partners, signaling strong regional reach and potential for multi-region trials and local regulatory support.

Robust capabilities Full Phase I to IV and post-marketing services with certified clinicians, adherence to GCP, EMA, and FDA guidelines, and in-house drug storage and distribution facilities, enabling end-to-end trial management for diverse sponsors.

Client stickiness Over eighty percent of business from repeat clients indicates high client satisfaction and potential for upsell into expanded trial scopes, post-approval studies, or additional therapeutic areas with existing relationships.

Leadership and CNS focus Recent hires and executive appointments in CNS and strategic leadership, plus active participation in CNS and ophthalmology events, suggest targeted opportunities with biotech and pharma players pursuing CNS/ophthalmology programs.

Growth signals Revenue range positions GCT as a mid-to-large CRO with ambitious expansion via global events, partnerships, and an increasing client base, making it a compelling option for sponsors seeking scalable, compliant trial execution.